PL1765816T3 - Podstawione propiolilopiperazyny o powinowactwie do receptora MGLUR5, do leczenia stanów bólowych - Google Patents

Podstawione propiolilopiperazyny o powinowactwie do receptora MGLUR5, do leczenia stanów bólowych

Info

Publication number
PL1765816T3
PL1765816T3 PL05756539T PL05756539T PL1765816T3 PL 1765816 T3 PL1765816 T3 PL 1765816T3 PL 05756539 T PL05756539 T PL 05756539T PL 05756539 T PL05756539 T PL 05756539T PL 1765816 T3 PL1765816 T3 PL 1765816T3
Authority
PL
Poland
Prior art keywords
substituted
mglur5 receptor
propiolylpiperazines
affinity
order
Prior art date
Application number
PL05756539T
Other languages
English (en)
Inventor
Sven Kühnert
Stefan Oberbörsch
Michael Haurand
Ruth Jostock
Klaus Schiene
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of PL1765816T3 publication Critical patent/PL1765816T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/42Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
PL05756539T 2004-07-05 2005-07-05 Podstawione propiolilopiperazyny o powinowactwie do receptora MGLUR5, do leczenia stanów bólowych PL1765816T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004032567A DE102004032567A1 (de) 2004-07-05 2004-07-05 Substituierte 1-Propiolyl-piperazine
PCT/EP2005/007248 WO2006002981A1 (de) 2004-07-05 2005-07-05 Substituierte 1-propiolyl-piperazine mit affinität für den mglur5 rezeptor zur behandlung von schmerzzuständen
EP05756539A EP1765816B1 (de) 2004-07-05 2005-07-05 Substituierte 1-propinoyl-piperazine mit affinität für den mglur5 rezeptor zur behandlung von schmerzzuständen

Publications (1)

Publication Number Publication Date
PL1765816T3 true PL1765816T3 (pl) 2010-08-31

Family

ID=34971564

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05756539T PL1765816T3 (pl) 2004-07-05 2005-07-05 Podstawione propiolilopiperazyny o powinowactwie do receptora MGLUR5, do leczenia stanów bólowych

Country Status (13)

Country Link
US (1) US7300939B2 (pl)
EP (1) EP1765816B1 (pl)
JP (1) JP5022218B2 (pl)
AT (1) ATE460413T1 (pl)
CA (1) CA2572685A1 (pl)
CY (1) CY1110127T1 (pl)
DE (2) DE102004032567A1 (pl)
DK (1) DK1765816T3 (pl)
ES (1) ES2342473T3 (pl)
PL (1) PL1765816T3 (pl)
PT (1) PT1765816E (pl)
SI (1) SI1765816T1 (pl)
WO (1) WO2006002981A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531529B2 (en) * 2003-06-05 2009-05-12 Roche Palo Alto Llc Imidazole derivatives
WO2005037805A2 (en) * 2003-10-15 2005-04-28 Sumitomo Chemical Company, Limited 1,2,4-thiadiazole compounds and pests controlling composition containing the same
KR101057032B1 (ko) 2004-06-01 2011-08-16 에프. 호프만-라 로슈 아게 Mglu5 수용체 길항제로서 피리딘-4-일-에틴일-이미다졸및 피라졸
EP2362310B1 (en) 2005-03-16 2017-10-04 III Holdings 12, LLC Automatic workload transfer to an on-demand center
DE102005023784A1 (de) * 2005-05-19 2006-11-30 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005062990A1 (de) 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Thiazole und ihre Verwendung zur Herstellung von Arzneimitteln
DE102005062991A1 (de) 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Thiazole und ihre Verwendung zur Herstellung von Arzneimitteln
DE102005062986A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
GB0602335D0 (en) * 2006-02-07 2006-03-15 Remynd Nv Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases
US8541406B2 (en) 2006-02-07 2013-09-24 Nv Remynd Thiadiazole derivatives for the treatment of neurodegenerative diseases
GB0623258D0 (en) 2006-11-22 2007-01-03 Remynd Nv Thiadiazole derivatives for the treatment of neuro-degenerative diseases
CN101679261A (zh) * 2007-03-09 2010-03-24 阿斯利康(瑞典)有限公司 哌嗪和哌啶mGluR5增效剂
CN105541769A (zh) 2007-06-29 2016-05-04 奥克塞拉有限公司 用于治疗眼科疾病和紊乱的炔基苯基衍生化合物
AU2008277730B2 (en) * 2007-07-13 2013-01-31 Addex Pharma S.A. Pyrazole derivatives as modulators of metabotropic glutamate receptors
CA2749163A1 (en) 2009-01-14 2010-07-22 The Salk Institute For Biological Studies Methods for screening and compounds that protect against amyloid diseases
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
ES2540956T3 (es) * 2011-07-01 2015-07-15 Remynd Nv Derivados de 1,2,4-tiadiazol-5-ilpiperazina útiles en el tratamiento de enfermedades neurodegenerativas
CA2841037C (en) * 2011-08-17 2020-03-31 Remynd Nv Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease
CN105837503A (zh) * 2016-05-12 2016-08-10 蚌埠中实化学技术有限公司 一种6-溴喹啉的制备方法
CN107325284B (zh) * 2017-07-02 2020-01-14 苏州大学 一种超支化聚苯基三唑甲酸酯及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56120669A (en) * 1980-02-27 1981-09-22 Res Inst For Prod Dev Allophanoylpiperazine compound and analgesic agent containing the same as active constituent
EP0552418A1 (en) * 1992-01-13 1993-07-28 Takeda Chemical Industries, Ltd. N-substituted-3-iodopropiolamide, production and use thereof
AUPQ386899A0 (en) * 1999-11-04 1999-11-25 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds
WO2003093236A1 (en) * 2002-05-02 2003-11-13 Euro-Celtique, S.A. 1-(pyrid-2-yl)-piperazine compounds as metabotropic glutamate receptor inhibitor
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain

Also Published As

Publication number Publication date
CA2572685A1 (en) 2006-01-12
EP1765816B1 (de) 2010-03-10
CY1110127T1 (el) 2015-01-14
DE502005009201D1 (de) 2010-04-22
DK1765816T3 (da) 2010-06-14
JP5022218B2 (ja) 2012-09-12
DE102004032567A1 (de) 2006-03-02
US7300939B2 (en) 2007-11-27
ES2342473T3 (es) 2010-07-07
JP2008505149A (ja) 2008-02-21
US20070112011A1 (en) 2007-05-17
SI1765816T1 (sl) 2010-07-30
ATE460413T1 (de) 2010-03-15
WO2006002981A1 (de) 2006-01-12
EP1765816A1 (de) 2007-03-28
PT1765816E (pt) 2010-06-14

Similar Documents

Publication Publication Date Title
SI1765816T1 (sl) Substituirani 1-propiolil-piperazini z afiniteto za MGLUR5 receptor za zdravljenje bolečih stanj
IL163629A0 (en) Glutaminyl derivatives and pharmaceutical compositions containing the same
EP1796678A4 (en) CARBOXAMIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS
GEP20074197B (en) 5ht2c receptor modulators
TW200505903A (en) CGRP receptor antagonists
YU84603A (sh) Novi inhibitori tirozin kinaze
MXPA04007470A (es) Piridinonas sustituidas.
WO2001081310A8 (en) 1-aroyl-piperidinyl benzamidines
HK1068136A1 (en) Muscarinic antagonists
IL151626A0 (en) Quinazoline compounds
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
IL176546A0 (en) Imidazoline derivatives having cb1-antagonistic activity
ZA200500951B (en) Azabicyclo derivatives as muscarinic receptor antagonists
HK1069169A1 (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
MXPA05010824A (es) Compuestos biciclicos como antagonistas del receptor nr2b.
WO2003099266A3 (en) Acetamides and benzamides that are useful in treating sexual dysfunction
MXPA06003363A (es) Derivados de fenil-piperazina como moduladores de receptores muscarinicos.
MXPA02011418A (es) 1-aminoalquil-lactamas sustituidas y su uso como antagonistas del receptor muscarinico.
MXPA05013151A (es) 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b.
SI1716128T1 (sl) Substituirane 4,5,6,7-tetrahidro-benzotiazol-2-ilaminske spojine
IL156140A0 (en) Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence
GB0019008D0 (en) Therapeutic compounds
GB0223223D0 (en) Organic compounds
RS20050738A (en) Pharmaceutical combination for the treatment of s pasticity and/or pain
UA84737C2 (ru) Производные имидазолина с антагонистической активностью относительно cb1